Roche’s Genentech signed a collaboration with Earendil Labs to discover and develop multiple bispecific antibodies for oncology. Roche will pay $55 million upfront, with milestones that could lift the deal’s total value above $1.5 billion, according to the reported terms. The partnership adds another discovery engine to Roche’s oncology pipeline, focused on bispecific modalities designed to improve therapeutic window and tumor targeting. It also reflects how increasingly competitive the bispecific race has become, as large pharma seeks faster candidate generation from specialized platform companies. For Earendil, the funding supports continued program execution, while for Roche it strengthens internal and external option-building ahead of future clinical readouts and potential label expansions across multiple tumor types.